Pharmacolog announces Investment Memorandum and date for investor meetings before a rights issue
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE PUBLISHED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, USA OR ANY OTHER JURISDICTION WHERE PUBLICATION OR DISTRIBUTION OF THE INFORMATION IS AGAINST, OR REQUIRES REGISTRATION, ACCORDING TO APPLICBLE RULES.
Pharmacolog in Uppsala AB (publ) (“Pharmacolog” or “The Company”) has prepared an Investment Memorandum regarding the forthcoming new issue of shares with preferential rights for the Company’s existing shareholders, which was published on 10 May 2019 (the “Rights Issue”). The Investment Memorandum is now available on the Company’s website and will be made available on Mangold Fondkommission AB’s website.
Application forms, teaser and other information regarding the Rights Issue will be available on the Company’s and Mangold’s websites as of May 21, 2019 when the subscription period commences. The record date for receiving subscription rights is May 17, 2019 and the last day for trading including the right to subscription rights is May 15, 2019.
In connection with the Rights Issue, Pharmacolog will attend investor meetings in Stockholm and Malmö.
May 20, 2019, Öresundsdagen in Malmö CEO Mats Högberg is presenting 14:00 to 14:30 Clarion Hotel & Congress Malmö, Sweden
June 3, 2019, Mangold Insights Investment Day CEO Mats Högberg is presenting 15:40 to 16:00 Scandic Anglais, Stockholm, Sweden.
Registration for Öresundsdagen in Malmö is made through the Aktiespararna and the registration for Mangold Insight’s Investment Day is made to email@example.com or via mangold.se/investerdagen.
Mangold Fondkommission AB is financial advisor and the law firm Lindahl KB is legal advisor to Pharmacolog in connection with the Rights Issue.
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
Publishing or distributing this press release may, in certain jurisdictions, be subject to law and law enforcement in those jurisdictions where this press release has been published or distributed should inform and comply with such legal restrictions. This press release does not constitute an offer or invitation to acquire or subscribe for any securities in Pharmacolog in any jurisdiction.
This press release does not constitute an offer to acquire securities in the United States. The securities mentioned herein may not be sold in the United States without registration in accordance with the U.S. Pat. The Securities Act of 1933 or without the application of an exception to such registration. The information contained in this press release may not be published, published or distributed, directly or indirectly, to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where disclosure, publication or distribution of the information would be in violation of applicable rules.
This press release is not a prospectus. Invitation to interested persons to subscribe for shares in Pharmacolog will only take place through the investment memorandum.